Publications by authors named "Michael A Zielinski"

Claim this Profile
C
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Michael A Zielinski

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy.
Neal D Shore, Michael S Broder, Pedro C Barata, Tony Crispino, André P Fay, Michael A Zielinski

Eur Urol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Michael A Zielinski

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and caregiver preferences on treatment attributes for atopic dermatitis.
Claire Ervin, Rebecca Crawford, Emily Evans, Steven R Feldman, Joshua Zeichner, Michael A Zielinski

J Dermatolog Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
Thomas A Luger, Adelaide A Hebert, Andrea L Zaenglein, Jonathan I Silverberg, Huaming Tan, Michael A Zielinski

Paediatr Drugs· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
Jonathan I Silverberg, Anna M Tallman, William C Ports, Robert A Gerber, Huaming Tan, Michael A Zielinski

Acta Derm Venereol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical Agents for the Treatment of Atopic Dermatitis.
Lawrence F. Eichenfield, Thomas Luger, Kim Papp, Jonathan I. Silverberg, Debra Sierka, Michael A. Zielinski

J Drugs Dermatol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
Robert Bissonnette, Ana B Pavel, Aisleen Diaz, John L Werth, Chuanbo Zang, Michael A Zielinski

J Allergy Clin Immunol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
Valerie D Callender, Andrew F Alexis, Linda F Stein Gold, Mark G Lebwohl, Amy S Paller, Michael A Zielinski

Am J Clin Dermatol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
Eric L Simpson, Gil Yosipovitch, Andrew G Bushmakin, Joseph C Cappelleri, Thomas Luger, Michael A Zielinski

Acta Derm Venereol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of Topical Treatments for Atopic Dermatitis.
Zoe D Draelos, Steven R Feldman, Brian Berman, Melissa Olivadoti, Debra Sierka, Michael A Zielinski

Dermatol Ther (Heidelb)· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
Emma Guttman-Yassky, Jon M Hanifin, Mark Boguniewicz, Andreas Wollenberg, Robert Bissonnette, Michael A Zielinski

Exp Dermatol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient impact and economic burden of mild-to-moderate atopic dermatitis.
Adelaide A Hebert, Georg Stingl, LoAn K Ho, Charles Lynde, Joseph C Cappelleri, Michael A Zielinski

Curr Med Res Opin· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.
Sonja Ständer, Thomas Luger, Joseph C Cappelleri, Andrew G Bushmakin, Carla Mamolo, Michael A Zielinski

Acta Derm Venereol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of cetirizine on symptom severity and quality of life in perennial allergic rhinitis.
David P Skoner, Craig F LaForce, Robert A Nathan, Eduardo R Urdaneta, Michael A Zielinski

Allergy Asthma Proc· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis